Physician profile
Safi Mohammed
NPI 1891100889
$13,269.28
in general payments reported to CMS, 2019-2025
33 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $598 · 2021: $3,144 · 2022: $273 · 2023: $345 · 2024: $6,084 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,875 · Food and Beverage: $1,912 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,875.00 |
| Food and Beverage | $1,911.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $5,223.24 | 2019-2024 | Speedicath |
| Teleflex LLC | $3,374.03 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $1,451.07 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, General - Kidney Stone Disease |
| Olympus Winter & Ibe Gmbh | $875.00 | 2025 | Endoeye Flex Deflectable Videoscope |
| Medivators INC. | $500.00 | 2021 | |
| Astellas Pharma US INC | $306.29 | 2019-2021 | |
| Antares Pharma, INC. | $297.89 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Neotract INC. | $184.42 | 2019-2020 | |
| Allergan, INC. | $160.80 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $136.53 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Procept Biorobotics Corporation | $88.85 | 2021-2025 | |
| Bluewind Medical | $69.92 | 2024 | Revi |
| Intuitive Surgical, INC. | $64.38 | 2019 | |
| Ambu INC. | $59.32 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $48.35 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $47.54 | 2021 | |
| Blue Earth Diagnostics | $40.93 | 2021 | |
| Medtronic USA, INC. | $36.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.24 | 2020 | |
| Richard Wolf Medical Instruments Corp. | $29.80 | 2019-2020 | |
| Myovant Sciences INC. | $27.99 | 2021 | |
| Abbvie INC. | $24.41 | 2022 | |
| Amgen INC. | $20.95 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $20.85 | 2021 | |
| Axonics, INC. | $20.29 | 2020 | |
| Olympus America INC. | $20.25 | 2023 | Olympus |
| Janssen Biotech, INC. | $19.84 | 2021 | |
| Dendreon Pharmaceuticals LLC | $16.97 | 2019 | |
| Endo Pharmaceuticals INC. | $15.49 | 2019 | |
| 180 Medical, INC. | $14.68 | 2021 | |
| Rochester Medical Corporation | $14.62 | 2019 | |
| Medtronic, INC. | $13.82 | 2021 | |
| Halozyme INC | $13.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safi Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.